Lupus Trial, Recruiting NCT07282392 Sponsor: University of Utah Condition: Lupus
Back to Lupus

Lupus Trial, Recruiting

NCT07282392
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • Adults between 18 and 65 years old, of any gender
  • People who have been diagnosed with both lupus and fibromyalgia or chronic widespread pain by a licensed rheumatologist
  • People whose medications have remained the same and stable without changes

Who may not be able to join:

  • People with serious psychiatric conditions (such as schizophrenia or bipolar disorder) that are not controlled by medication
  • People who are currently experiencing thoughts of suicide
  • People with an alcohol or substance use disorder that is not being treated
  • People with significant difficulties with memory, thinking, or understanding
  • People whose medications have changed in the past 3 months
  • People who are currently taking part in another treatment study
  • People who are currently involved in a legal case or disability application related to their health
  • People who are unable to use a computer and/or smartphone
  • People with little or no access to the internet
  • People who are unable to communicate in English
  • People who do not complete the required assessments at the start of the study

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 22 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Dan Kaufmann, PhD, University of Utah

Phone: 385-351-9058

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
1 December 2025
Est. completion
15 October 2028

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Widespread pain index at baseline; Widespread pain index a week after treatment compared to baseline; Symptom Severity Score at baseline; Change in the severity scale after treatment compared to baseline.

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov